Last checked at 7 Dec 2017 16:28
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to certain of its directors and senior management to acquire a total of 156,087 ordinary shares of 1.5p each in the capital of the Company under the Company's newly adopted 2017 Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options will vest after 3 years only if certain performance criteria are met. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
a. | Name | 1. Gordon Powell 2. Gino Miele 3. Nancy Neilson
| ||||||||||||
2. | Reason for the notification | |||||||||||||
a. | Position/status | 1. Commercial Director 2. R&D Director 3. Quality Assurance Director
| ||||||||||||
a. | Initial notification /Amendment | Initial notification | ||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a. | Name | genedrive plc | ||||||||||||
b. | LEI | 213800ZYODIRZ87Y4K14 | ||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1.5 pence each | ||||||||||||
b. | Nature of the transaction | Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017. | ||||||||||||
c. | Price(s) and volume(s) |
| ||||||||||||
d. | Aggregated information · Aggregated volume · Price
|
N/A
| ||||||||||||
e. | Date of the transaction | 2017-12-07; UTC time | ||||||||||||
f. | Place of the transaction | Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options | ||||||||||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO | |
Matthew Fowler: CFO | |
Peel Hunt LLP | +44 (0)207 418 8900 |
James Steel | |
Oliver Jackson | |
Consilium Strategic Communications | +44 (0)203 709 5700 |
Chris Gardner | |
Matthew Neal | |
Laura Thornton | |
genedrive@consilium-comms.com |